Trevigen是一家疾速生长的美国生物手艺公司，专一于细胞凋亡、DNA毁伤和修复、肿瘤细胞功效与行动等方面研讨的肿瘤研讨产物和办事。Trevigen公司位于NIH地点地的马里兰州盖瑟斯堡环球著名的270州际高速公路旁的高手艺走廊。Trevigen品牌的产物经由过程收集、目次、杂志告白、邮件和德律风等体例停止环球营销。其分销商已遍布北美，欧洲和环承平洋地域。Trevigen是一家以研发见长的企业，一向获得National Institutes of Health的SBIR基金撑持，其产物经由过程当局和大学投标，与至公司签定贴牌条约，国际代办署理商分销等体例行销环球。Trevegen其专一的成长理念，当真的品德把关，使它成为NIH周边浩繁手艺企业中妥当的气力派。
2008年Trevigen成立了一个全新的部分，Trevigen Cell Assays(TCA) ，首要营业是为生物制药企业、当局和学术机构供给研讨使命外包办事，可为客户设想和实行基于DNA毁伤、修复与癌症细胞的行动先导化合物和遗传毒性挑选尝试。
Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 "High technology Corridor" in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, catalog, journal advertising, direct mail, and telemarketing. Distributor appointments have been made in North America, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. The previous decade saw a phenomenal increase in the number of investigators studying apoptosis, but only recently has the link between DNA damage and apoptosis received significant attention. We are pleased to continue to support the growing numbers of investigators moving into these overlapping fields of research. A logical extension of our focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. As always, Trevigen brand products are manufactured to the highest standards of quality and backed by expert technical support.
Trevigen Cell Assays, (TCA) a division of Trevigen, Inc, was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the research